Urogen Pharma (URGN) News Today

Urogen Pharma (NASDAQ: URGN) shares have decreased despite several constructive developments, as investors weigh strong ZUSDURI sales and revenue growth against an ongoing quarterly loss and a slight EPS miss.

• Positive Sentiment: HC Wainwright raised its price target to $75 from $45 and reiterated a Buy rating. The new target implies approximately 64.5% upside from the referenced $45.60 price, signaling increased analyst confidence in Urogen’s commercial outlook. Benzinga The Fly
• Positive Sentiment: Second-quarter revenue was $72.46 million, above the $63.55 million analyst estimate. The company reported $50.4 million in ZUSDURI revenue, providing evidence of meaningful commercial traction and supporting the bullish analyst view. Urogen second-quarter financial results
• Neutral Sentiment: Management discussed the second-quarter results and company outlook during its earnings call, which investors may use to assess ZUSDURI’s sales trajectory, operating plans, and path toward profitability. Urogen Q2 2026 earnings call transcript
• Negative Sentiment: Urogen reported a quarterly loss of $0.28 per share, slightly worse than the $0.26 consensus estimate. Although the loss improved substantially from $1.05 per share a year earlier, continued losses and the EPS miss may be prompting profit-taking after the stock’s sharp run-up. Urogen earnings report